

# CITATION REPORT

List of articles citing

## Isolation and characterization of DNA from the plasma of cancer patients

DOI: 10.1016/0277-5379(87)90266-5  
European Journal of Cancer & Clinical Oncology, 1987,  
23, 707-12.

**Source:** <https://exaly.com/paper-pdf/19139951/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
272	A Possible Relationship Between Serum Satellite DNA and Cellular Antioxidative Mechanism. <b>1991</b> , 24, 865-871		
271	Extracellular DNA level in the blood of irradiated rats. <b>1992</b> , 62, 667-71		11
270	Blood levels of extracellular DNA in irradiated rats. <b>1992</b> , 113, 248-252		2
269	Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. <b>1994</b> , 86, 774-9		299
268	Extracellular nucleic acids as possible messengers in regulatory information transfer from immune system to non-lymphoid tissues. <b>1995</b> , 44, 435-8		1
267	Cancer and mutant DNA in blood plasma. <b>1996</b> , 348, 628		16
266	Microsatellite alterations in serum DNA of head and neck cancer patients. <b>1996</b> , 2, 1035-7		522
265	Nucleic acid-based methods for the detection of cancer. <b>1997</b> , 278, 1054-9		332
264	Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer. <i>British Journal of Cancer</i> , <b>1997</b> , 76, 1293-9	8.7	136
263	Mutations of p53 gene can be detected in the plasma of patients with large bowel carcinoma. <b>1998</b> , 51, 611-3		13
262	Detection and clinical importance of micrometastatic disease. <b>1999</b> , 91, 1113-24		415
261	Diagnosis of pancreatico-biliary malignancy: Detection of gene mutations in plasma and stool. <b>1999</b> , 10, S114-S117		10
260	Microsatellite abnormalities in plasma of patients with breast carcinoma: concordance with the primary tumour. <b>1999</b> , 52, 363-6		21
259	K-ras point mutations in the supernatants of pancreatic juice and bile are reliable for diagnosis of pancreas and biliary tract carcinomas complementary to cytologic examination. <b>1999</b> , 90, 240-8		20
258	Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients. <i>British Journal of Cancer</i> , <b>1999</b> , 80, 1262-4	8.7	102
257	Plasma Nucleosome Levels in Node-Negative Breast Cancer Patients. <b>1999</b> , 6, 361-364		37
256	Molecular methods for the diagnosis of cancer. <b>1999</b> , 1423, C11-8		10

255	Molecular genetic characteristics of lung cancer--useful as real' tumor markers?. <b>1999</b> , 25, 7-24	16
254	Detection of microsatellite alterations in nipple discharge accompanied by breast cancer. <b>2000</b> , 60, 35-41	10
253	Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia. <b>2000</b> , 92, 148-53	143
252	Plasma DNA, prediction and post-traumatic complications. <b>2001</b> , 313, 81-5	17
251	Detecting rare mutations associated with cancer risk. <b>2001</b> , 1, 283-93	7
250	Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. <b>2001</b> , 41, 276-82	225
249	Tumor-related alterations in circulating DNA, potential for diagnosis, prognosis and detection of minimal residual disease. <b>2001</b> , 15, 289-91	27
248	Tumor-specific DNA in plasma of breast cancer patients. <b>2002</b> , 13, 353-7	10
247	Circulating DNA in plasma and serum: biology, preanalytical issues and diagnostic applications. <b>2002</b> , 40, 962-8	31
246	Cell-free DNA: measurement in various carcinomas and establishment of normal reference range. <b>2002</b> , 321, 77-87	180
245	Circulating DNA: a new diagnostic gold mine?. <b>2002</b> , 28, 255-71	182
244	Targeting lethal minimal residual disease in small cell lung cancer. <b>2003</b> , 30, 79-85	27
243	Cell-free DNA is released from tumor cells upon cell death: a study of tissue cultures of tumor cell lines. <b>2003</b> , 17, 103-7	39
242	Measurement of an apoptotic product in the sera of breast cancer patients. <b>2003</b> , 39, 769-74	102
241	Role of macrophages in the generation of circulating blood nucleosomes from dead and dying cells. <i>Blood</i> , <b>2003</b> , 102, 2243-50	2.2 76
240	Release of DNA from dead and dying lymphocyte and monocyte cell lines in vitro. <b>2004</b> , 60, 159-66	72
239	Circulating nucleic acids and proteomics of plasma/serum: clinical utility. <b>2004</b> , 1022, 1-8	51
238	Quantification of circulating DNA in the plasma and serum of cancer patients. <b>2004</b> , 1022, 17-24	71

237	Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer. <b>2004</b> , 6, 101-7	163
236	Les acides nucléiques solubles dans le sang : intérêts et perspective. <b>2004</b> , 19, 3-12	
235	The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells. <b>2005</b> , 115, 55-62	146
234	Quantitative analysis of plasma TP53 249Ser-mutated DNA by electrospray ionization mass spectrometry. <b>2005</b> , 14, 2956-62	35
233	Improved method for isolating cell-free DNA. <b>2005</b> , 51, 1561-3	51
232	Sensitive detection of human papillomavirus in cervical, head/neck, and schistosomiasis-associated bladder malignancies. <b>2005</b> , 102, 7683-8	59
231	Diagnostische Bedeutung zirkulierender DNA- Fragmente in der Onkologie. Diagnostic importance of circulating DNA fragments in oncology. <b>2005</b> , 29,	
230	Detection of circulating tumor cells and of tumor DNA in plasma during tumor progression in rats. <b>2005</b> , 217, 115-23	28
229	Molecular biomarkers for cancer detection in blood and bodily fluids. <b>2006</b> , 43, 497-560	13
228	The epigenetics of oral cancer. <b>2006</b> , 35, 101-8	81
227	Low correspondence between K-ras mutations in pancreatic cancer tissue and detection of K-ras mutations in circulating DNA. <b>2006</b> , 32, 171-7	42
226	Low-molecular-weight DNA in blood plasma as an index of the influence of ionizing radiation. <b>2001</b> , 945, 221-8	21
225	Quantitative aspects of plasma/serum DNA in cancer patients. <b>2000</b> , 906, 5-7	27
224	An overview on the isolation and analysis of circulating tumor DNA in plasma and serum. <b>2000</b> , 906, 8-12	89
223	Profile of proteins complexed with circulating DNA of a lung cancer patient. <b>2000</b> , 906, 51-4	1
222	Detection of DNA in the plasma of septic patients. <b>2000</b> , 906, 134-40	26
221	The origin and mechanism of circulating DNA. <b>2000</b> , 906, 161-8	254
220	Microsatellite alterations detected in the serum of early stage breast cancer patients. <b>2001</b> , 945, 22-30	23

219	Comparisons between capillary zone electrophoresis and real-time PCR for quantification of circulating DNA levels in human sera. <b>2006</b> , 838, 122-8	8
218	Circulating DNA: intracellular and intraorgan messenger?. <b>2006</b> , 1075, 21-33	13
217	Genomic profiling of circulating plasma RNA for the analysis of cancer. <b>2007</b> , 53, 1860-3	27
216	Specific real-time PCR vs. fluorescent dyes for serum free DNA quantification. <b>2007</b> , 45, 993-5	19
215	Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. <b>2007</b> , 635, 105-117	325
214	Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer. <b>2007</b> , 13, 421-6	90
213	Extracellular nucleic acids. <b>2007</b> , 29, 654-67	126
212	Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer. <b>2007</b> , 120, 1465-71	48
211	Circulating nucleic acids (CNAs) and cancer--a survey. <b>2007</b> , 1775, 181-232	421
210	Circulating and imaging markers for angiogenesis. <b>2008</b> , 11, 321-35	38
209	Alternating current electrokinetic separation and detection of DNA nanoparticles in high-conductance solutions. <b>2008</b> , 29, 1765-74	70
208	Circulating DNA. Its origin and fluctuation. <b>2008</b> , 1137, 18-26	144
207	Integrity of cell-free plasma DNA in patients with lung cancer and nonmalignant lung disease. <b>2008</b> , 1137, 207-13	40
206	An improved method for the isolation of free-circulating plasma DNA and cell-free DNA from other body fluids. <b>2008</b> , 1137, 135-9	34
205	The concentration of deoxyribonucleic acid in plasma from 73 patients with colorectal cancer and apparent clinical correlations. <b>2008</b> , 32, 39-44	19
204	Identification of loss of heterozygosity on circulating free DNA in peripheral blood of prostate cancer patients: potential and technical improvements. <b>2008</b> , 54, 688-96	36
203	An AC electrokinetic method for enhanced detection of DNA nanoparticles. <b>2009</b> , 2, 253-61	24
202	Quantification of free total plasma DNA and minimal residual disease detection in the plasma of children with acute lymphoblastic leukemia. <b>2009</b> , 88, 897-905	20

201	Free DNA in the blood serum can unmask MYCN amplified tumors. <b>2009</b> , 53, 306-7	1
200	B1 sequence-based real-time quantitative PCR: a sensitive method for direct measurement of mouse plasma DNA levels after gamma irradiation. <b>2009</b> , 74, 1592-9	13
199	The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy. <b>2009</b> , 286, 29-37	91
198	Clinical use of circulating nucleosomes. <b>2009</b> , 46, 1-24	139
197	Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. <b>2009</b> , 64, 92-7	106
196	[Free circulating DNA based colorectal cancer screening from peripheral blood: the possibility of the methylated septin 9 gene marker]. <b>2009</b> , 150, 969-77	7
195	Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours. <b>2010</b> , 4, 11-21	33
194	Low correspondence of EGFR mutations in tumor tissue and paired serum of non-small-cell lung cancer patients. <b>2010</b> , 22, 27-31	5
193	Circulating free tumor DNA and colorectal cancer. <b>2010</b> , 34, 662-81	45
192	Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. <b>2010</b> , 116, 1918-25	116
191	Increased integrity of circulating cell-free DNA in plasma of patients with acute leukemia. <b>2010</b> , 48, 1651-6	45
190	Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. <b>2010</b> , 38, 6159-75	207
189	The Biology of Circulating Nucleic Acids in Plasma and Serum (CNAPS). <b>2010</b> , 167-189	14
188	Rapid Isolation and Detection of Cell Free Circulating DNA and Other Disease Biomarkers Directly from Whole Blood. <b>2010</b> , 247-257	1
187	Analysis of GD2/GM2 synthase mRNA as a biomarker for small cell lung cancer. <b>2010</b> , 67, 216-20	2
186	Cell-free DNA in the blood as a solid tumor biomarker--a critical appraisal of the literature. <b>2010</b> , 411, 1611-24	255
185	Circulating nucleic acids in cancer and pregnancy. <b>2010</b> , 50, 302-7	45
184	Validation of a blood plasma separation system by biomarker detection. <b>2010</b> , 10, 1587-95	53

183	Prognostic biomarkers in ovarian cancer. <b>2010</b> , 8, 231-51		25
182	Recovering circulating extracellular or cell-free RNA from bodily fluids. <b>2011</b> , 35, 580-9		77
181	Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients. <i>Clinical and Translational Oncology</i> , <b>2011</b> , 13, 677-85	3.6	27
180	Measurement of circulating cell-free DNA levels by a new simple fluorescent test in patients with primary colorectal cancer. <b>2011</b> , 135, 264-70		58
179	Screening and early detection of lung cancer. <b>2011</b> , 17, 3-10		42
178	Cell-free DNA as a biomarker in the context of cancer, viruses, and methylation. <b>2012</b> , 205, 1032-4		4
177	Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation. <b>2012</b> , 40, e82		283
176	Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. <b>2012</b> , 22, 220-31		152
175	Detection and identification of plasma bacterial and viral elements in HIV/AIDS patients in comparison to healthy adults. <b>2012</b> , 18, 1126-33		44
174	Dielectrophoretic isolation of DNA and nanoparticles from blood. <b>2012</b> , 33, 2482-90		52
173	LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival. <b>2012</b> , 12, 325		32
172	Circulating cell-free DNA: an up-coming molecular marker in exercise physiology. <b>2012</b> , 42, 565-86		128
171	The value of blood plasma low-molecular-weight DNA for diagnostics of pathological processes of different genesis. <b>2012</b> , 6, 278-287		
170	Circulating cell-free nucleic acids: promising biomarkers of hepatocellular carcinoma. <b>2012</b> , 39, 440-8		30
169	Epigenetic markers of prostate cancer in plasma circulating DNA. <b>2012</b> , 21, 3619-31		42
168	Quantitation of cell-free DNA and RNA in plasma during tumor progression in rats. <i>Molecular Cancer</i> , <b>2013</b> , 12, 8	42.1	28
167	Bridging the clinical gaps: genetic, epigenetic and transcriptomic biomarkers for the early detection of lung cancer in the post-National Lung Screening Trial era. <b>2013</b> , 11, 168		39
166	Dielectrophoretic isolation and detection of cfc-DNA nanoparticulate biomarkers and virus from blood. <b>2013</b> , 34, 1076-84		54

165	Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients. <b>2013</b> , 433, 227-34	74
164	Hide and seek: tell-tale signs of breast cancer lurking in the blood. <b>2013</b> , 32, 289-302	13
163	Circulating cell free DNA: Preanalytical considerations. <b>2013</b> , 424, 222-30	365
162	Cell-free DNA for the detection of pancreatic, liver and upper gastrointestinal cancers: has progress been made?. <b>2013</b> , 9, 1861-9	5
161	Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients. <b>2013</b> , 13, 827-44	84
160	From the Genetic Make-Up to the Molecular Signature of Non-Coding RNA in Breast Cancer. <b>2014</b> , 129-154	
159	Circulating miR-21, miR-146a and Fas ligand respond to postmenopausal estrogen-based hormone replacement therapy—a study with monozygotic twin pairs. <b>2014</b> , 143-144, 1-8	35
158	Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. <b>2014</b> , 20, 430-5	474
157	Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. <b>2014</b> , 406, 6499-512	204
156	Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer. <b>2014</b> , 8, 927-41	145
155	Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies. <b>2014</b> , 51, 200-31	57
154	Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. <b>2014</b> , 4, 650-61	473
153	Extracellular DNA and histones: double-edged swords in immunothrombosis. <b>2015</b> , 13 Suppl 1, S82-91	135
152	Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. <i>PLoS ONE</i> , <b>2015</b> , 10, e0140712	3-7 442
151	An electrochemical clamp assay for direct, rapid analysis of circulating nucleic acids in serum. <b>2015</b> , 7, 569-75	198
150	Blood Tests for Colorectal Cancer Screening in the Standard Risk Population. <b>2015</b> , 11, 397-407	4
149	Detecting cancer biomarkers in blood: challenges for new molecular diagnostic and point-of-care tests using cell-free nucleic acids. <b>2015</b> , 15, 1187-200	35
148	Near infrared Raman spectroscopic characterization of blood plasma of normal, oral premalignant and malignant conditions—a pilot study. <b>2015</b> , 46, 735-743	14



147	Measurement of circulating cell-free DNA levels by a simple fluorescent test in patients with breast cancer. <b>2015</b> , 143, 18-24	41
146	Chromosomal instability in cell-free DNA is a serum biomarker for prostate cancer. <b>2015</b> , 61, 239-48	35
145	Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. <b>2015</b> , 61, 297-304	194
144	Origins, structures, and functions of circulating DNA in oncology. <b>2016</b> , 35, 347-76	370
143	Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients. <b>2016</b> , 22, 5497-5505	96
142	The role of ctDNA detection and the potential of the liquid biopsy for breast cancer monitoring. <b>2016</b> , 16, 751-5	15
141	The Long and Short of Circulating Cell-Free DNA and the Ins and Outs of Molecular Diagnostics. <b>2016</b> , 32, 360-371	188
140	Nucleic Acids as Cancer Biomarkers in Circulation. <b>2016</b> , 125-152	
139	A historical and evolutionary perspective on the biological significance of circulating DNA and extracellular vesicles. <b>2016</b> , 73, 4355-4381	28
138	Quality assurance and standardization in view of non-invasive prenatal testing (NIPT). <b>2016</b> , 40,	1
137	Circulating biomarkers to monitor cancer progression and treatment. <b>2016</b> , 14, 211-22	95
136	Elevated Cell-Free DNA Measured by a Simple Assay Is Associated With Increased Rate of Colorectal Cancer Relapse. <b>2016</b> , 145, 852-7	9
135	Circulating cell-free nucleic acids as biomarkers in colorectal cancer screening and diagnosis. <b>2016</b> , 16, 239-52	22
134	Actin-resistant DNase I Expression From Oncolytic Adenovirus Enadenotucirev Enhances Its Intratumoral Spread and Reduces Tumor Growth. <b>2016</b> , 24, 796-804	21
133	Liquid biopsy: unlocking the potentials of cell-free DNA. <b>2017</b> , 471, 147-154	30
132	Current status of non-invasive prenatal testing in Japan. <b>2017</b> , 43, 1245-1255	26
131	CTCs and ctDNA: Two Tales of a Complex Biology. <b>2017</b> , 119-137	1
130	Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing. <b>2017</b> , 11, 208-219	83

129	Application of liquid biopsy in precision medicine: opportunities and challenges. <b>2017</b> , 11, 522-527	72
128	Direct detection of early-stage cancers using circulating tumor DNA. <b>2017</b> , 9,	537
127	Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary. <b>2017</b> , 77, 4238-4246	69
126	Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma. <b>2017</b> , 27, 81-87	50
125	Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer. <b>2017</b> , 12, 258-268	52
124	Oncogenic mutations of PIK3CA and HRAS in carcinoma of cervix in South Indian women. <b>2017</b> , 3, 112-116	2
123	Circulating cell-free DNA and circulating tumor cells, the "liquid biopsies" in ovarian cancer. <b>2017</b> , 10, 75	48
122	Analysis of circulating tumor DNA in breast cancer as a diagnostic and prognostic biomarker. <i>Cancer Genetics</i> , <b>2018</b> , 228-229, 159-168	2.3 24
121	The Liquid Biopsy, What is it, How is it Provided, and What is the Role of the Pulmonologist. <b>2018</b> , 25, 33-38	
120	The diverse origins of circulating cell-free DNA in the human body: a critical re-evaluation of the literature. <b>2018</b> , 93, 1649-1683	116
119	Preconcentration of DNA using magnetic ionic liquids that are compatible with real-time PCR for rapid nucleic acid quantification. <b>2018</b> , 410, 4135-4144	36
118	Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. <b>2018</b> , 19, 269-285	235
117	Cell-free nucleic acids in urine as potential biomarkers of kidney disease. <b>2018</b> , 16, 157-164	3
116	Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective. <b>2018</b> , 18, 7-17	102
115	Circulating V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma.. <b>2018</b> , 2, 1-11	3
114	[Liquid biopsy: a possible approach for cancer screening]. <b>2018</b> , 34, 824-832	2
113	Potential clinical applications of circulating cell-free DNA in ovarian cancer patients. <b>2018</b> , 20, e6	13
112	Increased Plasma Circulating Cell-Free DNA Could Be a Potential Marker for Oral Cancer. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3 30

111	Circulating Tumor Cells and Circulating Tumor DNA. <b>2018</b> , 235-281		6
110	Liquid Biopsy in Multiple Myeloma. <b>2018</b> ,		4
109	The Omics Revolution Continues: The Maturation of High-Throughput Biological Data Sources. <b>2018</b> , 27, 211-222		9
108	Fe-Au Nanoparticle-Coupling for Ultrasensitive Detections of Circulating Tumor DNA. <b>2018</b> , 30, e1801690		35
107	Circulating Cell-Free DNA in Hepatocellular Carcinoma: Current Insights and Outlook. <b>2018</b> , 5, 78		31
106	Circulating Cell-Free DNA as a Prognostic and Molecular Marker for Patients with Brain Tumors under Perillyl Alcohol-Based Therapy. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	18
105	Identifying exposures to ribosome-inactivating proteins in blood samples: amplification of ricin-induced ribosomal damage products enables sensitive detection of active toxin and circulating depurinated 28S rRNA. <b>2018</b> , 36, 375-384		1
104	Enrichment technique to allow early detection and monitor emergence of KRAS mutation in response to treatment. <b>2019</b> , 9, 11346		7
103	Clinical significance of cell-free DNA as a prognostic biomarker in patients with diffuse large B-cell lymphoma. <b>2019</b> , 54, 114-119		8
102	Advances in Directly Amplifying Nucleic Acids from Complex Samples. <b>2019</b> , 9,		12
101	Use of circulating nucleic acids, metabolites, and proteins as clinical biomarkers for earlier prognosis and diagnosis of disease. <b>2019</b> , 85-116		1
100	The potential of circulating cell free RNA as a biomarker in cancer. <b>2019</b> , 19, 579-590		13
99	TP53, EGFR and PIK3CA gene variations observed as prominent biomarkers in breast and lung cancer by plasma cell-free DNA genomic testing. <b>2019</b> , 300, 87-93		13
98	Recent Advances in Liquid Biopsy in Precision Oncology Research. <b>2019</b> , 42, 337-342		20
97	Genomic Medicine-Progress, Pitfalls, and Promise. <b>2019</b> , 177, 45-57		75
96	Quantifying circulating cell-free DNA in humans. <b>2019</b> , 9, 5220		76
95	Cell-free tumour DNA testing for early detection of cancer - a potential future tool. <b>2019</b> , 286, 118-136		23
94	Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA). <b>2019</b> , 23, 311-331		61

93	Liquid biopsy challenge and hope in colorectal cancer. <b>2019</b> , 19, 341-348		5
92	Early detection of pre-malignant lesions in a KRAS-driven mouse lung cancer model by monitoring circulating free DNA. <b>2019</b> , 12,		10
91	Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives. <b>2019</b> , 11, S113-S126		26
90	Guidelines for the Preanalytical Conditions for Analyzing Circulating Cell-Free DNA. <b>2019</b> , 65, 623-633		82
89	Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics. <b>2019</b> , 18, 1852-1862		13
88	A view on drug resistance in cancer. <b>2019</b> , 575, 299-309		606
87	High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. <b>2019</b> , 25, 1928-1937		263
86	Cell-free DNA as a biomarker of aging. <b>2019</b> , 18, e12890		43
85	Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the 'U' out of 'CUP'. <i>British Journal of Cancer</i> , <b>2019</b> , 120, 141-153	8.7	45
84	Using Digital Droplet Polymerase Chain Reaction to Detect the Mosaic GNAS Mutations in Whole Blood DNA or Circulating Cell-Free DNA in Fibrous Dysplasia and McCune-Albright Syndrome. <b>2019</b> , 205, 281-285.e4		7
83	Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies. <b>2019</b> , 66, e27595		24
82	Tumor-Based Genetic Testing and Familial Cancer Risk. <b>2020</b> , 10,		12
81	Cell-free DNA in hepatocellular carcinoma. <b>2020</b> , 199-209		0
80	Peritoneal Cell-Free Tumor DNA as Biomarker for Peritoneal Surface Malignancies. <b>2020</b> , 27, 5065-5071		4
79	Current therapy of advanced colorectal cancer according to RAS/RAF mutational status. <b>2020</b> , 39, 1143-1157		6
78	Expanding detection windows for discriminating single nucleotide variants using rationally designed DNA equalizer probes. <i>Nature Communications</i> , <b>2020</b> , 11, 5473	17.4	3
77	Putative Origins of Cell-Free DNA in Humans: A Review of Active and Passive Nucleic Acid Release Mechanisms. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	33
76	Circulating cell-free DNA is predominantly composed of retrotransposable elements and non-telomeric satellite DNA. <b>2020</b> , 313, 48-56		7

75	Liquid Biopsy: The Unique Test for Chasing the Genetics of Solid Tumors. <b>2020</b> , 13, 2516865720904052		24
74	Identification of Somatic Mutations in Thirty-year-old Serum Cell-free DNA From Patients With Breast Cancer: A Feasibility Study. <b>2020</b> , 20, 413-421.e1		1
73	Cell free DNA as a diagnostic and prognostic marker for cardiovascular diseases. <b>2020</b> , 503, 145-150		11
72	Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer. <i>Thoracic Surgery Clinics</i> , <b>2020</b> , 30, 165-177	3.1	5
71	Advances in bladder cancer biology and therapy. <i>Nature Reviews Cancer</i> , <b>2021</b> , 21, 104-121	31.3	80
70	Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients. <i>Nature Communications</i> , <b>2021</b> , 12, 11	17.4	40
69	Post-treatment cell-free DNA as a predictive biomarker in molecular-targeted therapy of hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , <b>2021</b> , 56, 456-469	6.9	2
68	Can Circulating Cell-Free DNA or Circulating Tumor DNA Be a Promising Marker in Ovarian Cancer?. <i>Journal of Oncology</i> , <b>2021</b> , 2021, 6627241	4.5	1
67	Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology. <i>Nature Biotechnology</i> , <b>2021</b> , 39, 1115-1128	44.5	31
66	Extracellular genetic materials and their application in clinical practice. <i>Cancer Genetics</i> , <b>2021</b> , 252-253, 48-63	2.3	0
65	Post-Biopsy Cell-Free DNA From Blood: An Open Window on Primary Prostate Cancer Genetics and Biology. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 654140	5.3	2
64	Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer. <i>Genome Medicine</i> , <b>2021</b> , 13, 89	14.4	0
63	Stance of MRD in Non-Hodgkin's Lymphoma and its upsurge in the novel era of cell-free DNA. <i>Clinical and Translational Oncology</i> , <b>2021</b> , 23, 2206-2219	3.6	0
62	A blood-based transcriptomic signature for noninvasive diagnosis of gastric cancer. <i>British Journal of Cancer</i> , <b>2021</b> , 125, 846-853	8.7	1
61	Diagnostic accuracy of Mycobacterium tuberculosis cell-free DNA for tuberculosis: A systematic review and meta-analysis. <i>PLoS ONE</i> , <b>2021</b> , 16, e0253658	3.7	1
60	The relevance of liquid biopsy in surgical oncology: The application of perioperative circulating nucleic acid dynamics in improving patient outcomes. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , <b>2021</b> ,	2.5	
59	Environmentally induced ribosomal DNA (rDNA) instability in human cells and populations exposed to hexavalent chromium [Cr (VI)]. <i>Environment International</i> , <b>2021</b> , 153, 106525	12.9	9
58	Observational study on serum markers and circulating tumor cells in ovarian cancer. <i>IP Archives of Cytology and Histopathology Research</i> , <b>2021</b> , 6, 181-186	0.8	

57	Size distribution of cell-free DNA in oncology. <i>Critical Reviews in Oncology/Hematology</i> , <b>2021</b> , 166, 103455		2
56	Prenatal Tarama Testleri ve H�reden BaĖns�z Fetal DNA. <i>Sleyman Demirel �iversitesi Tıp Fak�tesi Dergisi</i> ,		1
55	Circulating cell-free DNA in cancer. <i>Methods in Molecular Biology</i> , <b>2014</b> , 1160, 133-45	1.4	12
54	A Targeted Q-PCR-Based Method for Point Mutation Testing by Analyzing Circulating DNA for Cancer Management Care. <i>Methods in Molecular Biology</i> , <b>2016</b> , 1392, 1-16	1.4	10
53	Microsatellite Alterations as Diagnostic and Prognostic Molecular Markers in Patients With Cancer. <b>2004</b> , 395-428		2
52	Extracellular DNA in blood products and its potential effects on transfusion. <i>Bioscience Reports</i> , <b>2020</b> , 40,	4.1	3
51	Rearranged Ig Heavy Chain DNA Is Detectable in Cell-Free Blood Samples of Patients With B-Cell Neoplasia. <i>Blood</i> , <b>1997</b> , 90, 4953-4960	2.2	48
50	Rearranged Ig Heavy Chain DNA Is Detectable in Cell-Free Blood Samples of Patients With B-Cell Neoplasia. <i>Blood</i> , <b>1997</b> , 90, 4953-4960	2.2	3
49	Recovery of small DNA fragments from serum using compaction precipitation. <i>PLoS ONE</i> , <b>2012</b> , 7, e51863	3.7	4
48	Complete genes may pass from food to human blood. <i>PLoS ONE</i> , <b>2013</b> , 8, e69805	3.7	31
47	Marcadores tumorais no c�ncer de pulm�: um caminho para a terapia biol�gica. <i>Jornal De Pneumologia</i> , <b>2002</b> , 28, 143-149		1
46	[The value of low-molecular-weight DNA of blood plasma in the diagnostic of the pathological processes of different genesis]. <i>Biomeditsinskaya Khimiya</i> , <b>2013</b> , 59, 358-73	0.8	2
45	Efficacy of assessing circulating cell-free DNA using a simple fluorescence assay in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a prospective observational study. <i>Oncotarget</i> , <b>2018</b> , 9, 3875-3886	3.3	4
44	PIK3CA and KRAS mutations in cell free circulating DNA are useful markers for monitoring ovarian clear cell carcinoma. <i>Oncotarget</i> , <b>2018</b> , 9, 15266-15274	3.3	11
43	Tumor circulating DNA profiling in xenografted mice exposed to intermittent hypoxia. <i>Oncotarget</i> , <b>2015</b> , 6, 556-69	3.3	25
42	Cell-free tumor DNA: Emerging reality in oral squamous cell carcinoma. <i>Journal of Oral and Maxillofacial Pathology</i> , <b>2019</b> , 23, 273-279	1.2	3
41	Comparison of SUV Values Obtained from F-18 FDG PET/CT and Cell-free DNA Levels Measured from Plasma in Oncology Patients. <i>Molecular Imaging and Radionuclide Therapy</i> , <b>2019</b> , 28, 46-52	0.8	1
40	Further the liquid biopsy: Gathering pieces of the puzzle of genometastasis theory. <i>World Journal of Clinical Oncology</i> , <b>2017</b> , 8, 378-388	2.5	13

39	Our "Shagreen leather" is our problem. And we have to solve it. 3. A missing link. <i>Biopolymers and Cell</i> , <b>2003</b> , 19, 473-491	0.3	4
38	Autotransformation of mammalian cells. <i>Biopolymers and Cell</i> , <b>2005</b> , 21, 140-144	0.3	3
37	[Advance in human free circulating DNA]. <i>Yi Chuan = Hereditas / Zhongguo Yi Chuan Xue Hui Bian Ji</i> , <b>2008</b> , 30, 815-20	1.4	1
36	DNA Methylation in Tumor Diagnosis. <b>2008</b> , 319-332		
35	Color Plates. <b>2008</b> , 107-111		
34	Mitochondrial DNA Measurement in Exfoliated Cells for Cancer Detection and Monitoring: The Copy Number Advantage. <b>2010</b> , 259-274		
33	Präinatale Medizin – Entwicklung von der invasiven zur nichtinvasiven Diagnostik und von der Diagnose zur Therapie. <b>2011</b> , 311-333		
32	Extracellular DNA in oncological and other diseases related to apoptosis disorder. <i>Medical Alphabet</i> , <b>2019</b> , 3, 47-51	0.3	
31	Prenatal Screening for Fetal Aneuploidy. <i>Comprehensive Gynecology and Obstetrics</i> , <b>2021</b> , 49-56	0	
30	Using Liquid Biopsy in the Treatment of Patient with OS. <i>Advances in Experimental Medicine and Biology</i> , <b>2020</b> , 1257, 95-105	3.6	2
29	The contribution of the 20th century discoveries on the circulating DNA as biomarkers for cancer screening. <i>Anais Da Academia Brasileira De Ciencias</i> , <b>2020</b> , 92, e20200919	1.4	2
28	Prostate Cancer: Detection of Free Tumor-Specific DNA in Blood and Bone Marrow. <b>2008</b> , 481-497		
27	Study of the effect of argon glow discharge irradiation on the conformation of DNA molecules using laser spectroscopy methods. <i>Laser Physics Letters</i> , <b>2020</b> , 17, 115602	1.5	0
26	Non-Invasive Detection of Esophageal Cancer using Genetic Changes in Circulating Cell-Free DNA. <i>Avicenna Journal of Medical Biotechnology</i> , <b>2012</b> , 4, 3-13	1.4	9
25	Liquid biopsies in pediatric oncology: opportunities and obstacles. <i>Current Opinion in Pediatrics</i> , <b>2021</b> , 34,	3.2	0
24	At the dawn: cell-free DNA fragmentomics and gene regulation. <i>British Journal of Cancer</i> , <b>2021</b> ,	8.7	2
23	Tumor DNA in plasma of breast cancer patients. Relation to treatment. <b>2000</b> , 2, 141-145		
22	Emerging HER2-directed therapeutic agents for gastric cancer in early phase clinical trials.. <i>Expert Opinion on Investigational Drugs</i> , <b>2022</b> ,	5.9	3

21	Circulating tumor DNA (ctDNA) in adjuvant therapy of early stage colon cancer: current status and future perspectives.. <i>Acta Oncologica</i> , <b>2022</b> , 1-8	3.2	0
20	Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?. <i>British Journal of Cancer</i> , <b>2022</b> ,	8.7	4
19	Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer.. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
18	Urine as a non-invasive alternative to blood for germline and somatic mutation detection in hepatocellular carcinoma.		
17	Extracellular DNA Traps: Origin, Function and Implications for Anti-Cancer Therapies.. <i>Frontiers in Oncology</i> , <b>2022</b> , 12, 869706	5.3	2
16	The History and Future of Basic and Translational Cell-Free DNA Research at a Glance. <i>Diagnostics</i> , <b>2022</b> , 12, 1192	3.8	
15	Potential clinical utility of liquid biopsies in ovarian cancer.. <i>Molecular Cancer</i> , <b>2022</b> , 21, 114	42.1	1
14	Feasibility of Cell-Free DNA Measurement from the Earlobe during Physiological Exercise Testing. <i>Diagnostics</i> , <b>2022</b> , 12, 1379	3.8	
13	Clinical application and prospect of MRD evaluation in lung cancer based on ctDNA level: A review. <i>Tumori</i> , 030089162211019	1.7	
12	Circulating extracellular vesicles provide valuable protein, but not DNA, biomarkers in metastatic breast cancer. <b>2022</b> , 1,		
11	Early Detection of Relapse by ctDNA Sequencing in a Patient with Metastatic Thymic Tumor and MEN1 Mosaicism.		0
10	When Tissue Is the Issue. <b>2022</b> ,		
9	A standardised methodology for the extraction and quantification of cell-free DNA in cerebrospinal fluid and application to evaluation of Alzheimer's disease and brain cancers. <b>2022</b> ,		0
8	Combined plasma cell-free DNA detection and IFN- $\gamma$ /TNF- $\alpha$ dual fluorospot assays for diagnosing active tuberculosis.		0
7	Cell-Free DNA Fragmentomics: The Novel Promising Biomarker. <b>2023</b> , 24, 1503		0
6	Circulating DNA fragmentomics and cancer screening. <b>2023</b> , 3, 100242		2
5	Cell-Free DNA as a New Biomarker of IVF Success, Independent of Any Infertility Factor, Including Endometriosis. <b>2023</b> , 13, 208		0
4	Comparison of phenomics and cfDNA in a large breast screening population: the Breast Screening and Monitoring Study (BSMS).		0



- 3 Nurturing the marriages of urinary liquid biopsies and nano-diagnostics for precision urinalysis of prostate cancer. **2023**, 2,
- 2 Increased DNA content in stomach fluids: diagnostic implications of a possible new gastric cancer marker.
- 1 Sequence-Based Platforms for Discovering Biomarkers in Liquid Biopsy of Non-Small-Cell Lung Cancer. **2023**, 15, 2275